March 31, 2008 - Fifty-two week results of a two-year Phase III study of taranabant, Merck's investigational cannabinoid-1 receptor (CB1R) blocker, showed patients experienced statistically significant weight loss when taking the drug in combination with diet and exercise. These findings were presented today at the 57th annual scientific session of the American College of Cardiology... Merck's Press Release -
Thursday, April 3, 2008
Merck : Phase III Data Showed Taranabant, its Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
March 31, 2008 - Fifty-two week results of a two-year Phase III study of taranabant, Merck's investigational cannabinoid-1 receptor (CB1R) blocker, showed patients experienced statistically significant weight loss when taking the drug in combination with diet and exercise. These findings were presented today at the 57th annual scientific session of the American College of Cardiology... Merck's Press Release -